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Abstract
Background: Community-based cohort studies are not available that evaluated the predictive
power of both clinical and genetic risk factors for venous thromboembolism (VTE). There is,
however, clinical need to forecast the likelihood of future occurrence of VTE, at least qualitatively,
to support decisions about intensity of diagnostic or preventive measures.
Materials and methods: A 10-year observation period of the Bavarian Thromboembolic Risk
(BATER) study, a cohort study of 4337 women (18–55 years), was used to develop a predictive
model of VTE based on clinical and genetic variables at baseline (1993). The objective was to
prepare a probabilistic scheme that discriminates women with virtually no VTE risk from those at
higher levels of absolute VTE risk in the foreseeable future. A multivariate analysis determined
which variables at baseline were the best predictors of a future VTE event, provided a ranking
according to the predictive power, and permitted to design a simple graphic scheme to assess the
individual VTE risk using five predictor variables.
Results: Thirty-four new confirmed VTEs occurred during the observation period of over 32,000
women-years (WYs). A model was developed mainly based on clinical information (personal
history of previous VTE and family history of VTE, age, BMI) and one composite genetic risk
markers (combining Factor V Leiden and Prothrombin G20210A Mutation). Four levels of
increasing VTE risk were arbitrarily defined to map the prevalence in the study population: No/low
risk of VTE (61.3%), moderate risk (21.1%), high risk (6.0%), very high risk of future VTE (0.9%). In
10.6% of the population the risk assessment was not possible due to lacking VTE cases. The average
incidence rates for VTE in these four levels were: 4.1, 12.3, 47.2, and 170.5 per 104 WYs for no,
moderate, high, and very high risk, respectively.
Conclusion: Our prognostic tool – containing clinical information (and if available also genetic
data) – seems to be worthwhile testing in medical practice in order to confirm or refute the
positive findings of this study. Our cohort study will be continued to include more VTE cases and
to increase predictive value of the model.
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Background
Internationally there are several models available to assess
the long-term risk of cardiovascular disease and they are
broadly used in clinical practice and research [1-3]. A 10-
year risk prediction model based on clinical and labora-
tory data plays an integral part in planning cardiovascular
prevention [1]. However, this applies only for the arterial
side of the vascular system. We are not aware of any model
to predict the long-term risk for venous thromboembo-
lism (VTE) in a similar way.
A prediction of the absolute risk of venous thromboem-
bolism can only be developed on the basis of a specifically
designed long-term cohort study. The study reported here
is the first long-term, community-based cohorts study that
observed genetic and clinical thromboembolic risk factors
and their multivariate impact on VTE incidence to address
this issue in young women.
A population-based thromboembolic risk factor study
started in the mid-1990s in Bavaria, the BAvarian Throm-
boEmbolic Risk study (BATER), focused on women in the
reproductive age [4-6]. Clinical and laboratory risk factors
for VTE, the lifetime history of relevant conditions or
medications, and the family history of cardiovascular dis-
eases were documented from 1993 throughout the fol-
low-up period until 2003, i.e., carefully reviewing
complaints or findings possibly related to the occurrence
of venous clots.
This study provides a probability scheme that enables
identification of women at high risk for VTE compared to
women with virtually no risk for a theoretical period of
maximal 10 years (defined by the model used). These
findings could contribute to weigh the prognostic impor-
tance of clinical and laboratory data for medical decisions
and better counseling of patients.
Methods
Material and methods of this long-term cohort study has
been described in detail in earlier publications [4-6]. In
brief, we used a cohort of 4337 young women (18–55
years) in Bavaria (Germany) who had at least one follow-
up.
We collected data from demographics, reproductive life,
lifestyle pattern, conditions/diseases, and particularly
potential risk factors for VTE through a questionnaire for
self-administration. Whenever possible, time-related
information was documented. Using this method we were
able to set up the common starting point for the cohort as
1993. Telephone enquiries were made to supplement,
clarify and verify the data in the questionnaires.
The primary source for the data on VTE was the follow-up
questionnaire (self-reported VTE or symptoms potentially
compatible with VTE). This information was completed
by telephone interviews with the woman and with the
treating physician. All available information about diag-
nostic and therapeutic measures taken was recorded. Clin-
ical data and/or invasive or non-invasive diagnostic
procedures were assigned to one of the following catego-
ries of likelihood of a VTE:
Definite VTE
Unequivocal positive finding in at least one imaging test,
e.g., phlebography or duplex sonography for deep venous
thrombosis (DVT); pulmonary angiogram, VQ scan, spi-
ral computed tomography (spiral CT) for pulmonary
embolism (PE).
Probable VTE
Typical clinical symptoms for VTE without unequivocal
imaging test but positive findings in other diagnostic tests
(e.g. Doppler US or plethysmography) and subsequent
specific therapy over a longer period (low-dose heparin or
other anticoagulants).
Possible VTE
Typical clinical symptoms for VTE and unknown or equiv-
ocal result on imaging, only suspicion of VTE suggested by
a non-imaging diagnostic tests (such as Doppler US,
plethysmography, ECG, blood gas analysis or others for
PE) and no subsequent specific therapy (e.g., only short-
term low-dose heparin and bandage).
Potential VTE
Typical clinical symptoms for VTE without further diag-
nostic tests or negative results or diagnostics unknown.
Unspecific therapy – but nonetheless the treating physi-
cian maintained the diagnosis VTE based on clinical
findings.
All possible and potential "VTE cases" were excluded from
the analyses in this paper because of diagnostic uncer-
tainty, i.e. lacking information whether they should be
better classified as VTE cases or non-cases.
Women with a history of cancer or with known antiphos-
polipid syndrome were not in our follow-up study.
Laboratory methods
After having given informed consent the women included
in this study gave a blood sample at one time point during
the observational period (1996/97). An independent eth-
ics committee approved all study related activities.
Whole blood samples were obtained from resting sub-
jects. Blood was put into tubes with trisodium citrate.Thrombosis Journal 2005, 3:5 http://www.thrombosisjournal.com/content/3/1/5
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Plasma was prepared soon after venipuncture by centrifu-
gation for 15 minutes with 3000 to 4000 / min at room
temperature and stored at -20°C.
Protein C and antithrombin activities in plasma were
measured by chromogenic substrate assays (Dade
Behring, Marburg, Germany). For "antithrombin" the
activity against factor IIa was determined, Protein C activ-
ity was measured after activation of the proenzyme by
snake venom. Plasma activities are given as percentage
(units/dl) of pooled human normal plasma.
Genomic DNA was isolated by mean of QIAmp® DNA
Blood Kit (Qiagen) according to the manufacturer's
instructions. The genetic polymorphisms Factor V R506Q
(G1691A), the prothrombin promoter G2010A and the 5-
, 10-methylenetetrahydrofolate reductase (MTHFR)
A223V (C677T) were determined using a multiplex PCR
with allele-specific primers slightly modifying a previ-
ously described method [7].
All blood tests were performed blinded, i.e. the investiga-
tors had no clinical information, and had no access to the
clinical database.
Method of data analysis
Due to the importance of the temporal relationship the
database was structured to accommodate both concurrent
as well as time-dependent variables. Concurrent variables
are variables, which describe the woman's status at the
time of questionnaire response, whereas the outcome var-
iable (VTE) is time-dependent. While concurrent variables
were held in a fixed data set, a periodic data set containing
information on lifetime exposures and the occurrence of
VTE events along a time axis was created for the time-
dependent variables of each participant, using months as
a unit of measurement. The exposures of interest in this
publication, such as VTE risk factors including genetic
markers, refer to the baseline time point.
Some of the variables in the database (age, BMI, Protein
C, AT) were continuous. These variables were dichot-
omized in order to define a categorical exposure status
(exposed – non-exposed) for the analyses based on inci-
dence or logistic regression. We arbitrarily separated the
continuum in two roughly equal intervals such as age
under/over 30 or BMI under/over 25 in order to have suf-
ficient case numbers for analyses with further stratifica-
tion. For protein C and AT we used the 5th percentile
(lower 5% of the distribution in non-cases) as cut off
point. This limit was considered as usual definition for
deficiency and clinically relevant [8].
All analyses concerning the occurrence of VTE events over
time were performed by adding up individual observation
time (1993 until the last contact) for different exposure-
cohorts and in total. The incidence rate of VTE was calcu-
lated per 10,000 women years of observation (WY).
The predictive model was developed using the discrimi-
nant function analysis technique [9]. This technique per-
mits to determine which of the clinical and laboratory
data discriminate best between two groups: future VTE
cases vs. non-cases. In other words, this multivariate anal-
ysis determines which variables at baseline are the best
predictors of a future event.
We multivariately ranked the predictive power of the var-
iables with suspected effect on occurrence of VTE (i.e.,
possible or established risk factors). Other available infor-
mation in the database or information not known at base-
line (e.g. later occurring conditions like surgery or
longhaul flights; see discussion) were not included into
the model since they cannot contribute to a predictive
model (i.e. the setting for the application of the results of
this study is women consulted by a physician independ-
ent of an acute VTE event). Technically, we used stepwise
discriminant analysis with forward inclusion or backward
elimination of variables. The p-value for entry into the
model was 0.49 and for removal 0.50.
The p-value of the parameter provided by the discrimi-
nant analysis at the last step determines its rank. Variables
with the smallest p-value get the highest rank. This per-
mits the comparison of predictive power of potential risk
factors – documented at baseline (1993) – for later occur-
ring VTEs.
This technique permits to classify persons by the discrimi-
nant function value (separated by the case status). The
true incidence of new VTE cases was determined in strata
of persons with different pattern of risk profile to charac-
terize groups with lower or higher absolute VTE risk
according their risk profile at entry. We used for this anal-
ysis those variables that depicted the highest 5 ranks in the
stepwise discriminant analysis.
All analyses were performed with the statistical packages
SPSS 10.2, SAS 8.2 or STATA 8.2.
Results
Description of the cohort
The overall cohort encompasses 4337 women with suffi-
cient information in 1993 and one follow-up at mini-
mum. The observational period for our current analysis
was 32,656 WYs since 1993.
The follow-up was continued until 2003 at most, or was
otherwise terminated at the time when the last contact
was possible to get information about new conditionsThrombosis Journal 2005, 3:5 http://www.thrombosisjournal.com/content/3/1/5
Page 4 of 10
(page number not for citation purposes)
that may have had occurred. 2076 women could be fol-
lowed up until 2002/3 (47.9 %), 595 (13.7%) women
dropped out between 1999 and 2001, and the largest pro-
portion of women dropped out before 1999 (38.4%).
Thus, the follow-up period was censored some time
before 2002/3 for approximately half of the cohort
members.
Thirty-four new cases of VTE occurred in the observational
period. These cases were finally confirmed and catego-
Table 1: Distribution of 10 clinically and 5 genetically relevant variables in a cohort of young women at baseline of the observational 
period 1993 – 2003. The total number of women in this analysis is 4320, i.e. excluding 17 women with a final diagnosis of a possible/
potential VTE. Deviations from this number are due to missing data
Variables
Continuous variables n Mean (SD)
Age (years) 4320 26.0 (8.6)
Life births, number 1910 1.7 (0.8)
BMI§ 4309 23.3 (4.1)
Protein C (unit/dl) 4315 102.4 (15.8)
AT III (unit/dl) 4316 98.4 (11.3)
Categorical parameters Percent (%)
Own history of VTE No 4279 99.0
Yes 41 1.0
Family history No 3840 88.9
Yes 480 11.1
Age, alternative <30 2843 65.8
≥  30 1477 34.2
Family history of varicous veins No 2395 55.4
Yes 1925 44.6
Family history of MI No 3830 88.7
Yes 490 11.3
BMI, alternative <25 3218 74.7
≥  25 1091 25.3
Ever use of hormone replacement No 4031 93.7
Yes 270 6.3
Family history of stroke No 4013 92.9
Yes 307 7.1






Ever smoker No 2022 46.8
Yes 2296 53.2
Laboratory parameters
Factor V Leiden mutation1 No 4035 93.7
Yes 271 6.3
Prothrombin mutation1 No 4088 96.6
Yes 142 3.4
MTHFR1 No 1798 42.5
Yes 2432 57.5
Protein C: ≥  77(unit/dl) No 4117 95.4
<77 (5th percentile; unit/dl) Yes 198 4.6
AT III: ≥  81(unit/dl) No 4106 95.1
<81 (5th percentile; unit/dl) Yes 210 4.9
1 Homozygote & heterozygote together
§ Body mass index (kg/m2)Thrombosis Journal 2005, 3:5 http://www.thrombosisjournal.com/content/3/1/5
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rized according to diagnostic certainty by an independent
medical reviewer as definite (n = 31) or probable (n = 3).
Cases with possible/potential VTE (n = 17) were excluded
from further analyses because of low diagnostic certainty,
i.e. it was not clear whether to classify them in the group
"cases" or "non-cases".
Out of the 34 definite or probable VTE cases 18 cases (=
52.9%) were associated with "clinical causes for VTE" and
16 (= 47.1%) were so-called "idiopathic" VTEs. The fol-
lowing previously described "acute clinical causes" for
VTE the following were observed: 4 with previous VTE, 3
with pregnancy/delivery, 4 after accident, 2 after surgery,
3 with immobilization, and 2 after long travel.
Table 1 depicts the profile of relevant data available at
baseline (1993) to get an impression of the group under
follow-up.
The mean age was 26 ± 8.6 years, however, for the dichot-
omized age variable we used as cut-off point 30 years
resulting in strata that contained VTE cases in both age
groups. The frequency of other conditions, family history
of potentially relevant diseases, lifestyle pattern and
genetic tests is provided in the table 1. Homo-and hetero-
zygote carriers of mutations were analyzed together
because of small numbers of homozygote carriers.
Ranking risk factors according predictive power for VTE
The stepwise discriminant analysis was used to rank rele-
vant variables at baseline according to their power to pre-
dict the case and non-case status many years later. We
initially used 7 clinically available, potential risk factors
for VTE and 5 laboratory parameters. Later, we combined
genetic markers (Factor V Leiden and Prothrombin muta-
tion G20210A) together in one composite variable due to
low prevalence in the cases: FVL (n = 4) and PTM (n = 2).
We used only categorical variables in the model, i.e.,
dichotomized continuous variables.
We got the following ranking of the predictive power to
explain the occurrence of new VTE cases during a theoret-
ical 10-year period (defined by our model) in declining
order: Medical history of VTE, family history of VTE (1st
degree relatives), age at baseline 1993, body mass index
(BMI), factor V Leiden (FVL) or prothrombin mutation
(PTM), family history of varicose veins, protein C, AT
level, hormone ever use, MTHFR carrier status, and OC
ever use. We considered only the 5 highest-ranking varia-
bles for the development of our predictive model for prac-
tical use (Table 2). Seven other variables with lower
predictive importance were left out because their multi-
variate impact was too low and the practical application of
a model with more than 5 variables is not easy to handle
in practice. In addition, models that included other or
more than the selected 5 variables brought no further
improvement of the prediction (data not shown).
Taking the VTE incidence in all combinations of the five
variables into account, we formed four levels of future VTE
risk (Table 3). Some of the combinations of the five risk
markers had not sufficient data, i.e. the observation
period (WY) was too short to observe new VTE cases.
The majority of the study population (61.3%) had a small
VTE risk (no/low in Table 3), about 20% depicted a "mod-
erate risk", 6% a "high risk", and 0.9% a "very high risk".
About 10% could not be classified due to lacking VTE
cases in the observation period ("no data"). The cut points
for the four risk levels were arbitrarily defined: The average
VTE incidence per 104 WYs steeply increases across the five
groups: 4.1 (no/low), 12.3 (moderate), 47.2 (high), and
170.5 (very high).
Figure 1 provides a scheme to support the individual deci-
sion about a future VTE risk based on information on five
or less variables. The small number of new VTE cases in
our model, however, prevented us from drawing a com-
plete decision tree, i.e. some branches of the tree cases
were not observed yet or only one case (considered as not
sufficient to be included in the scheme). For example, the
small group of VTE cases with a previous history of a VTE
in our cohort (n = 4) did not allow for further specifica-
tion by age, family history of VTE, BMI, and genetic
marker: this group is associated with a very high risk alto-
gether, but it is not clear if subgroups may have a lower or
higher risk. Other examples were women without previ-
ous VTE history but positive family history of VTE, higher
age, and higher BMI: there were no cases to distinguish
between carriers of genetic markers (FVL or PTM positive)
and those without any positive genetic markers.
Table 2: Ranking order of clinical and laboratory data according, 
possibly relevant for VTE. Analysis with stepwise discriminant 
analysis
Rank order P value Independent variables
10 . 0 0 0 Medical history of VTE (yes, no)
20 . 0 0 5 Family history of VTE (yes, no)
30 . 0 1 2 Age at baseline 1993: <30 vs. ≥  30 years
40 . 0 8 2 BMI: <25 vs. ≥  25
50 . 1 1 2 FVL or PTM carrier: any positive vs. all negativ
60 . 1 5 3 Family history of varicose veins (yes, no)
70 . 5 3 6 Protein C: <77 vs. ≥  77(unit/dl)
80 . 7 6 7 AT III: <81 vs. ≥  81(unit/dl)
90 . 7 7 3 HRT ever use (yes, no)
10 0.776 MTHFR carrier (yes, no)
11 0.798 OC ever use (yes, no)Thrombosis Journal 2005, 3:5 http://www.thrombosisjournal.com/content/3/1/5
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Table 3: Expected risk level for VTE within next 10 years in four categories in the BATER study population: No/low risk, moderate risk, 
high risk, very high risk.
Future risk level Study population WY1 VTE cases VTE incidence
N% y e a r s N P e r  1 0 4WYs
No/low 2634 61.3 19282 8 4.1
Moderate 907 21.1 7314 9 12.3
High 257 6.0 2117 10 47.2
Very high 40 0.9 352 6 170.5
No data2 457 10.6 3300 0 0.0
1WY = representing the women-years of observation in the respective category of the BATER cohort)
2No cases observed in these sub-groups
Predicted risk for VTE within next 10 years in four categories: No/low risk (blank circles), moderate risk (dotted), high risk  (hatched), very high risk (black circles) Figure 1
Predicted risk for VTE within next 10 years in four categories: No/low risk (blank circles), moderate risk (dotted), high risk 
(hatched), very high risk (black circles). BMI = body mass index; FVL + PTM = Factor V Leiden mutation (hetero-&homozy-
gote) and /or prothrombin G20210A mutation (hetero-&homozygote) ; n.d. = no dataThrombosis Journal 2005, 3:5 http://www.thrombosisjournal.com/content/3/1/5
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Women without VTE history, no family history, young
and slim are privileged with low future VTE risk. With
increasing age and BMI the VTE risk increases, particularly
if associated with positive family history and markers for
inherited VTE risk. Using this scheme, it is also possible to
predict future VTE risk without knowledge about genetic
risk factors and to give appropriate advice.
Discussion
To our knowledge, long-term, community-based cohort
studies with the aim to evaluate or compare the predictive
power of clinical as well as genetic risk markers for VTE are
lacking. Most studies related to VTE risk factors were
restricted to clinically available markers such as age, BMI,
previous VTE, family history, or acute factors (immobili-
zation, surgery, accidents, pregnancy, and also hormone
use) and usually based on clinical observations or case-
control studies or studies in administrative databases, and
also a few cohort studies (overview about incidence and
risk factor studies in [10,11]). One recent publication of a
historic cohort [12] assessed carefully the impact of clini-
cal risk factors for the prevalence of VTE and determined
relative VTE risk estimates. Cohort studies in the popula-
tion rarely included/reported genetic markers for throm-
bophilia and acquired risk factors, except the Physicians
Health Study for example – however only for males over
40 years of age [13]. An important recently published
cohort study in Denmark analyzed specifically the inci-
dence of VTE and compared carriers of FVL compared with
non-carriers [14].
Other studies with focus on markers for hereditary throm-
bophilia were performed in patients (e.g. in anticoagula-
tion clinics), in relatives of carriers of genetic mutations
but not in the "normal female population" [15-18]. In
addition, the evaluation of the importance of genetic
markers for VTE risk does rarely consider the impact of
clinically available risk factors and the design is often
restricted to case-control studies. Overall different study
designs and restricted views may come to similar conclu-
sions in an ideal world, but not necessarily.
Our BATER cohort study covers more than 4,000 cohort
members with a fairly long observation period (1993 –
2003), translating into over 32,000 WYs. Thirty-four VTE
cases, classified as definite or probable, occurred within
this period. This is equivalent to an incidence of about 10
per 10,000 WYs. It is important to realize that we put great
effort on the detection of potential cases and – even more
important – we included all definite and probable cases,
whereas most reported incidence rates refer only to defi-
nite and so-called "idiopathic VTE", i.e. most reported
rates excluded all cases that occurred in temporal relation-
ship to possible "acute" causes such as pregnancy/deliv-
ery, surgery, and immobilization. Idiopathic VTEs,
however, reflect only a part of all confirmed VTE cases
[17]. We found in our cohort study roughly 50% so-called
"idiopathic" VTE cases, and the other 50% of cases had a
previous VTE in the past, pregnancy, delivery, surgery,
accident, or immobilization/long bed-rest shortly prior to
the VTE event. Thus, the incidence of "idiopathic VTE"
observed in this study would be 5 per 10,000 WYs and
thereby likely to be in the same range as other reported
incidence rates in the general population. The incidence
estimates for definite VTE ranges between 1 to 6 per 104
WYs in OC non-users and 2 to 10 per 104 WYs in OC users
[10]. Older studies depicted almost always-higher
incidence rates than more recently performed studies (see
overview in [10]). A recent systematic review [11] came to
a pooled incidence of definite VTE for the general popula-
tion of 5 per 10,000 person years, similar in males and
females, and found that around 40% of VTE cases were
"idiopathic". A large cohort study found a similar inci-
dence rate in males aged 40–49 years: 4.7/104 person-
years [13].
The objective of this study was to provide a simple algo-
rithm for medical practice to predict the future VTE risk
with a simple scheme based on usually available informa-
tion, i.e. to discriminate women with virtually no VTE risk
in the foreseeable future from those at a high absolute risk
to suffer from VTE. Incidence rates associated with differ-
ent clinical and genetic factors will be published sepa-
rately [6].
It is a limitation of this long-term cohort study, however,
that the number of confirmed (definitive and probable),
incident VTE cases was still too small in absolute numbers
(n = 34). In other words, some sub-cohorts with certain
combinations of risk factors did not contain one single
new VTE case. The consequence was that the number of
subgroups at risk was minimized to the extent possible to
make it a feasible tool for the practice. In so far, the results
and conclusions should be considered as rough but the
best we can possibly do at this stage, i.e. future analyses
will benefit from an improved point of departure (more
cases, longer observation). Another limitation is that we
did not have the chance yet to test the validity of the
model in another, independent cohort. This is a task for
the future. Therefore we focused this paper on a simple
scheme with a rough classification of the future VTE risk.
The interested (or worried) women and her treating phy-
sician might like to know (or to get confirmation)
whether the future VTE risk is higher than "normal" (no/
low risk). This information could have an impact on fur-
ther medical surveillance, especial counseling, proposals
as how to reduce of changeable risk factors or on sugges-
tions for preventive measures under certain circumstancesThrombosis Journal 2005, 3:5 http://www.thrombosisjournal.com/content/3/1/5
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and – of course- with respect to the compliance regarding
preventive measures.
Using stepwise discriminant analysis the rank order of 12
(11) clinical or laboratory data at baseline (1993) was
multivariately determined concerning the power to pre-
dict future VTEs. This was the information needed to
select a minimal set of parameter combinations to build a
"VTE prediction model". Finally we ended up with a
model covering the five variables with highest ranking
(impact) regarding predictive importance for future VTE
only: history of previous VTE, family history of VTE,
higher age, higher body mass index, and carrier of FVL or
PTM. The decision to form the composite genetic marker
"FVL or PTM" was guided by the small numbers of cases
who were carrier of this two mutations and the low pre-
dictive power of all other lab parameters we had in the
data set (see table 2).
Four levels of future VTE risk were arbitrarily defined-
based on a steeply increasing absolute VTE risk: No/low
risk (4 per 104 WY), moderate (12/104 WY), high risk (47/
104 WY), or very high (171/104 WY). The low-risk group
was chosen to reflect an assumed VTE risk of the normal
population (see above), the group with "moderate risk"
because VTE risk over 10/104 is indicative for an increased
risk, and the "high and very high risk" groups are clearly
out of the normal range. One should also consider in this
context, that these cut-off points reflect an average risk
with an assumed variation within these groups – as can be
seen in the scheme of a decision tree (figure 1).
In accordance with clinical experience the overwhelming
majority (61%) depicts a low risk of a future VTE. Only a
minority of 6% and 0.9% is facing a high or very high VTE
risk. The women who fall into the two highest risk catego-
ries have a previous own history of VTE or a positive VTE
family history, have a higher BMI or a genetic mutation
(FVL or PTM). Even though, the contribution of genetic
appears to be limited. Using an analysis based only on
clinically available data, i.e., without use of the informa-
tion about lab parameters, we arrived at very similar three
risk categories with almost identical absolute VTE risk
(data not shown separately but are part of Figure 1).
Another point for discussion is the impression suggested
by figure 1 that persons with previous VTE do not require
genetic testing because they are in the "high risk" category
without any further considerations. The risk might well be
different for persons with/without inherited risk (family
history), younger/higher age, or overweight. This however
we cannot further disentangle because we are lacking new
VTE events particularly in this high-risk group of our
study. Thus, the conclusions are rather crude as discussed
before and require clinical experience for the interpreta-
tion of individual cases. The need for genetic testing
depends on the judgment in a specific clinical situation
and the usefulness of this additional information for the
physician and/or the patient (family).
Decisions based on clinical variables about preventive
measures will be made in any case – even if no genetic
information is available. The possible approaches are a
matter of a current controversy in the literature
[15,20,21]. Clinical reports point often towards a high
VTE recurrence rate in patients with previous VTE [22], but
despite being the "best" single predictor we found this
phenomenon only in 4 of our 34 incident VTE cases.
The predictor variables used in our model seem to be
plausible and consistent with the clinical experience: His-
tory of previous VTE, age and obesity are indeed impor-
tant clinical information for the VTE risk assessment, and
also genetic marker were discussed as predictors of a
future VTE. These are also risk parameter that are com-
monly used when recommending preventive measures in
situations like long-haul flights, immobilization (such as
accidents, surgery) and are also labelled as risk factor in
drugs containing sexual hormones (e.g., oral contracep-
tives or hormone therapy).
We assume that physicians will appreciate these results as
a possibility to double-check if their own decision are sup-
ported by evidence coming from this large cohort study or
may even alter their decision. At least the proposed model
contains a reassuring element. It should be underlined
that these algorithms do not obviate the need of weighing
individual risks and benefits.
We conclude from our observation that the prediction of
future VTEs can well be done on clinical data alone – at
least until better genetic markers are established. In other
words, well-established genetic parameters alone are rela-
tively weak long-term risk factors, the occurrence of VTE
requires interaction of both inherited and acquired risk
factors [23]. Results of several recent studies support argu-
ments against the possibility that testing for
thrombophilia could help to better predict future VTEs
[15,20,21]. Nonetheless one can argue that genetic testing
in families with significant family history of VTE or
previous experience of a VTE might well give additional
information for clinical decisions and may increase efforts
to comply with preventive measures. The limitation of our
study is that we cannot further divide the risk spectrum in
these sub-groups due to small numbers of new events or
too short total WY of observation. In any case, when a
genetic test is recommended, the physician should know
how a positive test would influence his/her clinical judg-
ment [15]. These early results of our cohort study contrib-
ute to this interpretation or decision-making, respectively.Thrombosis Journal 2005, 3:5 http://www.thrombosisjournal.com/content/3/1/5
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Forecast of VTE risk cannot be based on genetic character-
istics alone but only in combination with important clin-
ical data (acquired risk information). Genetic markers
play obviously a limited role in the long-term prediction
of VTE – at least in the age group under 50. Genetic mark-
ers together with these "personal characteristics" consti-
tute the disposition. Family history of cardiovascular
events, specifically venous events have to be taken into
account. As described before and confirmed by our data
the probability whether the disposition translates into an
event is obviously more influenced by "personal charac-
teristics" such as higher age, or higher BMI. However,
there are obviously other important, more acutely affect-
ing environmental factors such as immobilization, sur-
gery, accidents, and treatment with drugs that influence
coagulation. The latter factors can be used to reduce the
risk as estimated by the model (or own clinical
experience).
Another issue for discussion is the validity of our calcu-
lated incidence rates: The lowest VTE incidence level
observed in this model was 4 per 10,000 WYs. Due to an
active search for findings compatible with the diagnosis of
VTE, the inclusion of definite and probable diagnosis as
well as of so-called "non-idiopathic VTEs", the incidence
figures were expected to be higher than in normal "medi-
cal statistics" or administrative databases as discussed
above. The equivalent incidence rate for only definite and
idiopathic VTE could be expected to be approximately 2
per 104 per year and therefore very low for women who
were using oral contraceptives as the average population.
We like to stress that our study was rigorous in document-
ing the VTE diagnosis. We conclude that the data can be
generalized for the female population in the fertile age
range. In analogy, the incidence might be compared with
results of a prospective, community-based cohort study
[13] that found in males aged 40–49 years a VTE inci-
dence rate of 2.7 primary VTEs cases per 104 person-years
(equal to idiopathic: no previous VTE history, no cancer,
no surgery or trauma).
The influence of other, more acutely acting risk modifiers
– such as immobilization, surgery, long-haul flights, and
use of drugs (e.g. OCs and other hormones) was inten-
tionally excluded from this model. Only parameters that
were available at baseline and likely to affect the long-
term development were eligible for this prognostic model.
We saw no possibility to introduce parameters in the
model that may or may not operate later, shorter or longer
during the observational period. In other words, only
long-term characteristics at baseline (both clinical and
genetic variables) were initially included into the mode-
ling. Other influential risk factors or preventive measures
have to be considered when discussing activities to reduce
a predicted increased risk in the medical practice. It was
not the aim of the study and data are neither available to
test the effect of preventive measures nor the effect of
additional risk factors in the immediate period before the
event occurred. This would require another study design
and a separate study with sufficient power for such
questions.
The variables selected for the model fit the expectations of
the skilled clinician. The model was developed to assist
physicians- we hope for feedback from medical practice.
This "prognostic model" seems to be worthwhile to be
tested in clinical practice. There is a minority of women
that would need additional genetic testing, intense coun-
seling, suggestions for risk reduction (if possible), and
efforts to prevent avoidable risk situations (e.g. treatment
with OCs or hormones) or to take other appropriate pre-
ventive measures in situation of an acute risk (immobili-
zation, surgery, long-haul flights and others), e.g.
compression stockings/ heparin. Several other options to
reduce the VTE risk profile are principally available, but
sometimes not easy to achieve (e.g. reduction of BMI).
Prevention of VTE in medical practice can be improved if
the main risk factors are known (importance to document
medical history and established risk factors), but also
knowledge of their relative importance in the risk-net-
work as well as of interactions with environmental factors.
The predictive models discussed in this paper may assist
doctors to pay particular attention to labeling prior to pre-
scription (e.g. oral contraceptives or hormones) and to
use convincing evidence-based data when counseling
women of a predicted higher risk.
We abstained – at the current stage – from the temptation
to use a complex equation to calculate an apparently exact
risk for the individual person (e.g., using a "risk calcula-
tor") because it suggests inadequate accuracy and we
rather prefer to provide a very simple scheme that can be
handled during routine work. Moreover, we are planning
a validation of this model in an independent cohort
study, as the first step the part related to clinical risk
factors.
Conclusion
Our prognostic tool – containing clinical information
(and if available also genetic data) – seems to be worth-
while testing in medical practice in order to confirm or
refute the positive findings of this study. Our cohort study
will be continued to include more VTE cases and to
increase predictive value of the model.
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